[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639343":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":20,"centralContacts":25,"locations":30,"responsibleParty":45,"collaborators":19,"id":47,"slug":19,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":19,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":19,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":33,"whyStopped":19,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Guangzhou Virotech Pharmaceutical Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":9,"interventionNames":11},"VRT106","EXPERIMENTAL",[12],"Drug: VRT106 for injection",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","VRT106 for injection","VRT106, iv",[9],null,[21],{"name":22,"affiliation":23,"role":24},"Yuanyuan Chen","Sun Yat-Sen University Cancer Center","STUDY_CHAIR",[26],{"name":22,"role":27,"phone":28,"phoneExt":19,"email":29},"CONTACT","202-87343543","chenyy2@sysucc.org.cn",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":19,"country":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Sun Yat-sen University Cancer Center","RECRUITING","Guangzhou","Guangdong","China",{"type":38,"coordinates":39},"Point",[40,41],113.25,23.11667,{"lat":41,"lon":40},[44],{"name":22,"role":27,"phone":28,"phoneExt":19,"email":29},{"type":46,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100639343",false,"NCT07589257","A Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma \u002F Diffuse Intrinsic Pontine Glioma","A Single-Arm, Open-Label, Multicenter Phase II Clinical Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma \u002F Including Diffuse Intrinsic Pontine Glioma","Inclusion Criteria:\n\n* Voluntary signing of the Informed Consent Form (ICF), indicating understanding of the study and willingness and ability to comply with all study procedures.\n* Male or female adults aged 18 to 75 years at the time of signing the ICF.\n* Histologically or cytologically confirmed H3 K27-altered diffuse midline glioma (DMG), or a diagnosis of DIPG based on brain contrast-enhanced MRI: tumor originating in the pons, occupying \\>50% of the pons volume, with diffuse brainstem enlargement.\n* Karnofsky Performance Status (KPS) score ≥ 60.\n* Expected survival time ≥ 3 months.\n\nExclusion Criteria:\n\n* Individuals with extracranial metastases.\n* Presence of spinal cord tumors or evidence of leptomeningeal disease dissemination.\n* Active hemorrhage detected on cranial MRI scan prior to enrollment.\n* Inability to undergo cranial MRI scanning (e.g., due to contraindications or incompatible implants).\n* Prior receipt of oncolytic virus therapy or other gene therapy agents.","ALL","18 Years","75 Years",{"count":57,"type":58},10,"ESTIMATED","INTERVENTIONAL",[61],"PHASE2","To Evaluate the Preliminary Efficacy and Safety\u002FTolerability of VRT106 Combined with Radiotherapy in Adult Patients with DMG\u002FDIPG",[64,65],"Diffuse Midline Glioma, H3 K27M-Mutant","Diffuse Intrinsic Pontine Glioma",[64,65],"2026-05-13",{"date":69,"type":70},"2026-05-15","ACTUAL",{"date":72,"type":58},"2026-05-07",{"date":74,"type":58},"2028-12-31",{"name":5,"class":6},1]